Showing 1 - 10 of 17
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
This report examines the key features of the Directive of the European Parliament and of the European Council on representative actions for the protection of the collective interests of consumers and its wider impact on consumer-led litigation across Europe, including comparative insights into national class action mechanisms in the United Kingdom, Belgium, Denmark, France, Portugal, Spain and Ireland.
In this Q&A, Jenny Yu, the Industry Practice Leader for Chemicals and Life Sciences in the UK at Marsh & McLennan shares her thoughts on the impact of COVID-19 on the life sciences sector.
On Monday 22 June 2020, the European Parliament and the European Council reached agreement on draft legislation that will introduce a standardised ‘collective action’ regime empowering qualified representative entities to bring collective actions and seek redress on behalf of groups of EU consumers in respect of infringements of EU law.
Case review 04/05/2020
In a reminder of the scrutiny to which the courts will use when reviewing costs budgets, the High Court has rejected an application by group litigation claimants to retrospectively revise a previously approved costs budget and reduced a future budget by more than half.
With the UK Government calling on organisations from a variety of industries to help solve the country’s COVID-19 ventilator shortage, we explore what organisations should consider when considering manufacturing ventilators.
We continue to assess the impact of the COVID-19 pandemic on the life sciences industry and in this update we consider the EU response to supply chain disruption, vaccine R&D and antibody testing kits.
As innovation and new technologies are rapidly transforming the way we live, it is imperative that businesses in all industries remain alive to the risks arising from these advancements.
Boris Johnson’s first Queen’s Speech delivered on Monday 14 October 2019 - dominated by Brexit-related legislation - included the Medicines and Medical Devices Bill (the Bill).
With the current Article 50 extension deadline of 31 October 2019 looming against a complex and uncertain political backdrop, and talks between the UK and EU continuing without any clear sign of a definitive outcome, the possibility of a no-deal Brexit remains at an all-time high.